US3478070A - Process for selectively acylating the 3-ol group in polyhydroxy 13-alkyl gona-(and 8 - isogona) - 1,3,5 - (10) - trienes and delta - 7 -,delta - 8(9),delta - 9(11) -,and delta - 8(9),14(15) - dehydro derivatives thereof - Google Patents
Process for selectively acylating the 3-ol group in polyhydroxy 13-alkyl gona-(and 8 - isogona) - 1,3,5 - (10) - trienes and delta - 7 -,delta - 8(9),delta - 9(11) -,and delta - 8(9),14(15) - dehydro derivatives thereof Download PDFInfo
- Publication number
- US3478070A US3478070A US693112A US3478070DA US3478070A US 3478070 A US3478070 A US 3478070A US 693112 A US693112 A US 693112A US 3478070D A US3478070D A US 3478070DA US 3478070 A US3478070 A US 3478070A
- Authority
- US
- United States
- Prior art keywords
- delta
- solvent
- methanol
- diol
- tetraene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 title description 41
- 230000008569 process Effects 0.000 title description 33
- 241001653109 Isogona Species 0.000 title description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 126
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 72
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical group COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 56
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical group [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 50
- 239000002904 solvent Substances 0.000 description 41
- 239000000243 solution Substances 0.000 description 38
- 239000000047 product Substances 0.000 description 36
- 239000000203 mixture Substances 0.000 description 28
- -1 alkali metal alkoxide Chemical class 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 238000003756 stirring Methods 0.000 description 24
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 150000003431 steroids Chemical class 0.000 description 18
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 238000005292 vacuum distillation Methods 0.000 description 14
- 238000004821 distillation Methods 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 229910052783 alkali metal Inorganic materials 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 235000019270 ammonium chloride Nutrition 0.000 description 8
- 239000012442 inert solvent Substances 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 150000001340 alkali metals Chemical class 0.000 description 6
- 150000004703 alkoxides Chemical class 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 125000002252 acyl group Chemical group 0.000 description 5
- 150000001266 acyl halides Chemical class 0.000 description 5
- 238000005917 acylation reaction Methods 0.000 description 5
- 150000002009 diols Chemical class 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 230000010933 acylation Effects 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000002402 anti-lipaemic effect Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000005672 tetraenes Chemical class 0.000 description 3
- 150000005671 trienes Chemical class 0.000 description 3
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IWTBVKIGCDZRPL-UHFFFAOYSA-N 3-methylpentanol Chemical compound CCC(C)CCO IWTBVKIGCDZRPL-UHFFFAOYSA-N 0.000 description 2
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 2
- 206010024434 Lichen sclerosus Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000012050 conventional carrier Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960003399 estrone Drugs 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- JILPJDVXYVTZDQ-UHFFFAOYSA-N lithium methoxide Chemical compound [Li+].[O-]C JILPJDVXYVTZDQ-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- DUCKXCGALKOSJF-UHFFFAOYSA-N pentanoyl pentanoate Chemical compound CCCCC(=O)OC(=O)CCCC DUCKXCGALKOSJF-UHFFFAOYSA-N 0.000 description 2
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 2
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 208000008480 vulvar lichen sclerosus Diseases 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- AEQRFPQMXCSUIN-YRXWBPOGSA-N (8S,9S,13S,14S)-13-ethyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene Chemical compound CC[C@@]12CCC[C@H]1[C@@H]1CCC=3C=CC=CC3[C@H]1CC2 AEQRFPQMXCSUIN-YRXWBPOGSA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- NLWBEORDOPDUPM-UHFFFAOYSA-N 1,2,3,4-cyclopentanetetracarboxylic dianhydride Chemical compound O=C1OC(=O)C2C1C1C(=O)OC(=O)C1C2 NLWBEORDOPDUPM-UHFFFAOYSA-N 0.000 description 1
- NLLMJANWPUQQTA-UHFFFAOYSA-N 13-methyl-6,9,11,12,14,15,16,17-octahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3=CCC2=C1 NLLMJANWPUQQTA-UHFFFAOYSA-N 0.000 description 1
- OGMHLZVDKIJTMN-UHFFFAOYSA-N 3-methylpentanoyl chloride Chemical compound CCC(C)CC(Cl)=O OGMHLZVDKIJTMN-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 1
- LEKJTGQWLAUGQA-UHFFFAOYSA-N acetyl iodide Chemical compound CC(I)=O LEKJTGQWLAUGQA-UHFFFAOYSA-N 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- AOMUALOCHQKUCD-UHFFFAOYSA-N dodecyl 4-chloro-3-[[3-(4-methoxyphenyl)-3-oxopropanoyl]amino]benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=C(Cl)C(NC(=O)CC(=O)C=2C=CC(OC)=CC=2)=C1 AOMUALOCHQKUCD-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- YWGHUJQYGPDNKT-UHFFFAOYSA-N hexanoyl chloride Chemical compound CCCCCC(Cl)=O YWGHUJQYGPDNKT-UHFFFAOYSA-N 0.000 description 1
- PKHMTIRCAFTBDS-UHFFFAOYSA-N hexanoyl hexanoate Chemical compound CCCCCC(=O)OC(=O)CCCCC PKHMTIRCAFTBDS-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- BWWYHSLPXSWCEC-UHFFFAOYSA-N methanolate;rubidium(1+) Chemical compound [Rb+].[O-]C BWWYHSLPXSWCEC-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- SYXYWTXQFUUWLP-UHFFFAOYSA-N sodium;butan-1-olate Chemical compound [Na+].CCCC[O-] SYXYWTXQFUUWLP-UHFFFAOYSA-N 0.000 description 1
- RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
Definitions
- This invention is concerned with the preparation of steroid compounds useful in therapy and as intermediates for therapeutically useful compounds. More particularly, it relates to a new and useful process for the selective acylation of the phenolic hydroXyl function of A-ring aromatic, polyhydroxylated steroids. Compounds prepared by this process are estrogenically and anti-lipemicallyactive and are important intermediates in the preparation of biologically active steroids.
- a primary object of this invention to provide a means selectively to acylate the 3-01 group in polyhydroxylated, A-ring aromatic steroids.
- R and Y are as hereinabove defined by:
- Step (a) said alkali metal alkoxide is sodium methoxide and said lower alkanol medium is methanol;
- Step (c) is carried out at a temperatureof from about 25 C. to about C. for from about 15 minutes to about three ours.
- l3-methylgona- 1,3,5 (10)8-tetraene-3,17fi-diol, 3-acetate is prepared by (a) reacting 13-methylgona-1,3,5(10),8-tetraene-3,17- diol with sodium methoxide in methanol;
- Step (c) reacting the mixture of Step (b) with acetic anhydride
- a process as first above defined wherein 13-ethylgona- 1,3,5 10),8-tetraene-3,17 ⁇ 3-diol, 3 acetate is prepared by (a) reacting 13 ethylgona-1,3,5(l),8-tetraene-3,17 ⁇ 3- diol with sodium methoxide in methanol;
- Step (c) reacting the mixture of Step (b) with acetic anhydride
- a process as first above defined wherein d-13-methylgona-1,3,5(l0)-triene-3,l7fi-diol, 3-acetate is prepared by (a) reacting d l3-methylgona-1,3,5(l0)-triene-3,17fldiol with sodium methoxide in methanol;
- Step (c) reacting the mixture of Step (b) with acetic anhydride
- a process as first above defined wherein l3-methylgona- 1,3,5(),7-tetraene-3,17 3-diol, 3-acetate is prepared by (a) reacting 13-methylgona-l,3,5(10),7-tetraene-3,l7fldiol with sodium methoxide in methanol;
- Step (c) reacting the mixture of Step (b) with acetic anhydride
- a process as first above defined wherein 13-ethylgona- 1,3,5 (10),9(l1)-tetraene-3,17,8-diol, 3-acetate is prepared y (a) reacting l3 ethylgona-1,3,5(10),9(l1)-tetraene-3, l7fl-diol with sodium methoxide in methanol;
- Step (c) reacting the mixture of Step (b) with acetic anhydride
- a process as first above defined wherein 13-ethylgona- 1,3,5 (l0),8,14-pentaene-3,17/3-diol, 3-acetate is prepared (a) reacting 13 ethylgona-1,3,5(10),8,l4-pentaene-3, 17/3-diol with sodium methoxide in methanol;
- Step (c) reacting the mixture of Step (b) with acetic anhydride; and 1 (d) recovering the product by removing the solvent by distillation in a vacuum.
- a process as first above defined wherein l3-ethylgona- 1,3,5 (10)-triene-3,16a,17fl-triol, 3-acetate is prepared by (a) reacting 13 ethylgona-1,3,5(10)-triene-3,16a,17,8- triol with sodium methoxide in methanol; I
- Step (c) reacting the mixture of Step (b) with acetic anhydride;;and H (d) recovering the product by removing the solvent by distillationin a vacuum.
- (lower)alkyl contemplates saturated hydrocarbon radito about 6 carbon atoms and includes, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, n-hexyl, 3-methyl pentyl, and the like.
- (lower)acyl contemplates alkanoyl groups, both straight chain or branched, or from about 1 to about 6 carbon atoms and includes, for example, formyl acetyl, n-propionyl, n-butyroyl, i-butyroyl, n-pentanoyl, n-hexanoyl, 3- methylpentanoyl, and the like.
- (lower) alkanol contemplates aliphatic alcohols, straight and branched chain, containing from about 1 to about 6 carbon atoms and includes, for example, methanol, ethanol, n-propanol, i-propanol, n-butanol, t-butanol, n-pentanol, n-hexanol, 3-methylpentanol, and the like.
- alkali metal (lower)alkoxide contemplates organometallic derivatives of lithium, potassium, sodium, cesium and rubidium and (lower) alkanols and includes, for example, sodium methoxide, potassium methoxide, lithium methoxide, cesium methoxide, rubidium methoxide, sodium ethoxide, sodium n-propoxide, sodium i-propoxide, sodium n-butoxide, sodium t-butoxide, potassium t-butoxide, sodium n-pentoxide, sodium n-hexoxide and the like.
- (lower)acyl anhydride contemplates compounds containing (lower)alkanoyl groups as above defined and includes, for example, acetic anhydride, n-propionic anhydride, n-butyric anhydride, i-butyric anhydride, n-pentanoic anhydride, n-hexanoic anhydride and the like.
- (lower)acyl halide contemplates lower(acyl) halogenides derived from fluorine, chlorine, bromine and iodine, the (lower)acyl group being as above illustrated, and includes, for example, acetyl fluoride, acetyl chloride, acetyl bromide, acetyl iodide, n-propionyl chloride, n-butyroyl chloride, i-butyroyl chloride, n-pentanoyl chloride, n-hexanoyl chloride, 3-methylpentanoyl chloride, and the like.
- polar inert solvent medium contemplates solvents, organic and inorganics, which are polar in nature and are not susceptible to reaction with (lower)acyl anhydrides or (lower)acyl halides under the conditions exemplified and includes, for example, ethylene glycol dimethyl ether, dioxane, dimethylformamide, dimethylacetamide, and the like.
- the 13-alkylgona 1,3,5(10) triene 3,17/3 diols of Formula II are prepared by means exemplified by Gordon Alan Hughes and Herchel Smith in copending US. patent application No. 534,353 filed Mar. 15, 196 6.
- the 13 alkyl 8 isogona 1,3,5(10) triene 3,17/3- diols of Formula II are prepared by means exemplified by Gordon Alan Hughes and Herchel Smith in copending US. patent application Ser. No. 461,909, filed June 7, 1965, now US. 3,407,217.
- the 13 alkylgona 1,3,5(l0),7 tetraene 3,175- diols of Formula II are prepared by means exemplified by R. P. Stein, G. C. Buzby, Jr., and Herchel Smith in copending US. patent application Ser. No. 559,175, filed June 21, 1966, now abondoned.
- the steroid of Formula II may be added to a mixture of the alkali metal (lower)alkoxide and the (lower)alkanol at any convenient temperature, e.g. from about 10 C. to
- reaction forming the anion salt especially at about 25 C., is quite rapid and 'is substantially complete almost instantaneously.
- Step (b) displacement of the (lower) alkanol by the polar inert solvent
- the acylating agent which may be a (lower)acyl anhydride, (lower)acyl halide, or obvious chemical equivalent thereof, such as, for example a (lower)acyl p-toluenesulfonate
- the acylating agent can be aded to the mixture at temperatures of from about 10 C. to about 150 C., but preferably at from about 25 C. to about 100 C. It is preferred to use at least about one equivalent amount of the acylating agent, or a slight excess, e.g., up to about a 10% excess, based on the steroid.
- the reaction forming the desired selectively acylated product is substantially complete, depending on the temperature, in from about 15 minutes to several, e.g., about 3, hours.
- Step (d) recovery of the product of Formula I according to Step (d) is accomplished by conventional methods.
- the product can be induced to precipitate by cooling the mixture, especially if it first has been concen trated, then the precipitate is recovered by filtration.
- One especially useful means is to distill oif all of the reaction solvent, leaving the product as a residue. To proceed in this manner, the solvent is distilled off in a vacuum. Any excess acylating agent can be decomposed by adding ammonium chloride solution.
- the mixture then can be extracted with a water immiscible organic solvent, such as ethyl acetate, and the extract can be washed with water, saturated sodium chloride solution and dried over anhydrous sodium sulfate.
- Evaporation of the solvent leaves the product of Formula I as a residue. If desired, it may be further purified by chromatography: it is dissolved in chloroform and passed through a column of active silica gel. The eluates can be combined and evaporated. The residue can often be induced to crystallize by trituration with ether or isopropanol and can be recrystallized from a (lower)alkanol.
- reaction temperatures appreciably below these can be used, but their use considerably extends the reaction time.
- reaction temperatures higher than those mentioned can be employed with a concomitant decrease in reaction time, although purity of the product may be somewhat decreased.
- the compounds of Formula I prepared by this process have estrogenic and antilipemic activity. This makes them useful to treat conditions in mammals responsive to treatment with estogenic drugs, such as, for example, menopause, senile vaginitis, kraurosis vulvae, pruritis vulvae and the like. In addition they are useful to lower blood lipid level of mammals and can be used whenever anti-lipemic agents are indicated, such as in the treatment of various hyperlipid aemias or where the incidence of atherosclerosis is to be minimized.
- the products prepared by the instant process are also useful as intermediates for the preparation of other steroids, such as 17a-ethynylestradiol as mentioned above which have hormonal or other useful activities.
- the products of Formula I prepared by this invention can be used in association with a pharmaceutically acceptable carrier. They can be formulated in liquid or solid forms, for instance as capsules, tablets, suppositories, powders, dispersible granules, cachets, and the like, by combining them with conventional carriers.
- Such conventional carriers include magnesium carbonate or stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, low melting wax and cocoa butter.
- Diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders or tablet-disintegrating agents can be used. Powders or tablets preferably contain 5 or 10 to 99% of the active constituent.
- the active steroid can be formulated with an encapsulating material with or Without other carriers.
- Liquid preparations such as solutions, suspensions or emulsions can also be used.
- Such preparations include dispersions in a pharmaceutically acceptable carrier such as arachis oil or sterile water, preferably containing a non-ionic surface active agent such as fatty acid esters of polyhydroxy compounds, e.g., sorbitan, aqueous starch in sodium carboxymethylcellulose solutions, aqueous propylene glycol or polyethylene glycol.
- a waterpropylene glycol solution can be used for parenteral injection and aqueous suspensions suitable for oral use can be made by utilizing natural or synthetic gums, resins, methyl cellulose or other well known suspending agents.
- the composition can be in unit dose form in which the dose unit is for instance from about 0.1 to about 200 mg. of each active steroid.
- the unit dose form can be a packaged composition, e.g., packeted powder, vials or ampules or, for example, in the form of capsules, cachets or tablets or any number of these in packaged form.
- the pharmaceutical compositions can also consist substantially solely of the active steroid when this is in unit dose form. When used for the purposes stated above, the dosage of the compounds will vary with the condition being treated, but in general Will be in the range established for estradiol (Merck Index, seventh edition, p. 416 (1960)).
- d-Estradiol-3-acetate one of the products prepared by the instantprocess (and which itself is the subject of US. 2,156,599), can be used at a level of 1.25 mg. daily, orally, in menopausal syndrome and from 1.25 to 3.75 mg. or more, daily, for senile vaginitis, kraurosis vulvae or pruritis vulvae, in warm blooded animals of about 70 kilogram average body weight, depending on the tissue response of the individual.
- useful substrates would be represented by the formula wherein n is at least two and R is a cyclopentanopolyhydrophenanthrene nucleus monohydroxylated in its aromatic A-ring which, on selective acylation at the 3-position, would provide a product with anti-lipemic and estrogenic activity.
- Example 1 dl-l3-methylgona-l, 3,5(10),8 tetraene-3,17,8 diol, 3- acetate.Add dl-l3-methylgona-1,3,5(l0), 8-tetraene-3, 17/3-diol, 2.70 g., to a solution of sodium methoxide (0.594 g.) in anhydrous methanol (40 ml.). Stir, then remove the solvent in vacuo. Add ethylene glycol dimethyl ether (100 ml.) to the residue and stir, then add a solution of acetic anhydride (1.12 g.) in ethylene glycol dimethyl ether (15 ml.). Stir the reaction for 15 min.
- Example 2 dl 13 ethylgona-1,3,5(),8-tetraene-3,17[3-diol, 3- acetate.Add dl 13 ethylgona-1,3,5(10),8-tetraene-3, 17fi-diol, 2.84 g., to a solution of sodium methoxide (0.550 g.) in anhydrous methanol (30 ml.). Stir the solution, then remove the solvent in vacuo. Add ethylene glycol dimethyl ether 100 ml.) to the residue and stir, then add acetic anhydride (1.12 g.). Stir the reaction at room temperature for min., heat on a steam bath for 15 min.
- Example 3 d-13-methylgona 1,3,5(10) triene-3,17fi-diol, 3acetate (d-estradiol3-acetate).Dissolve de-estradiol (2.72 g.) in a solution containing sodium methoxide (0.594 g.) in anhydrous methanol. ml.). Stir, then remove the methanol in vacuo. Add ethylene glycol dimethyl ether (100 ml.) to the residue, stir then add acetic anhydride (1.12 g.). Stir the reaction at room temperature for 15 min.,heat on a steam bath for 15 min. then stir again at room temperature for /2 hour.
- Example 4 d-13-rnethylgonal,3,5 10) ,7-tetraene-3,l7fl-diol, 3-acetate; (d-17-dihydroequilin-3-acetate).Dissolve d 17- dihydroequilin (5.40 g.) in a solution containing sodium methoxide (1.188 g.) in anhydrous methanol ml.). Stir then remove the solvent in vacuo. To the residue add ethylene glycol dimethyl ether (200 ml.), stir then add acetic anhydride (2.3 g.) and continue stirring at room temperature for 1 hour. Remove the solvent in vacuo.
- Example 5 dl 13 ethylgona 1,3,5(10),9(11)-tetraene-3,17/3- diol, 3-acetate.-Add dl-13-ethylgona-1,3,5(10),9(11)- tetraene-3,17,6-diol, 2.84 g., to a solution containing sodium methoxide (0.540 g.) in anhydrous methanol (40 ml.), stir then remove the solvent in vacuo.
- Example 6 dl-13-ethylgona-1,3,5(10),8,14-pentaene-3,17/3-diol, 3- acetate.-Add dl 13 ethylgona-1,3,5(10),8,14-pentaene- 3,17B-diol (1.41 g.) to a solution of sodium methoxide (0.275 g.) in anhydrous methanol (25 ml), stir then re move the methanol in vacuo. Add ethylene glycol dimethyl ether (100 ml.), stir then add a solution of acetic anhydride (0.510 g.) in ethylene glycol dimethyl ether (15 ml.). Warm the solution for 10 min.
- Example 7 r The procedure of Example 1 is repeated, substituting for the sodium methoxide, stoichiometrically equivalent amounts of the following alkali metal (lower )alkoxides: potassium methoxide, lithium methoxide, sodium ethoxide, potassium t-butoxide and sodium n-hexoxide. Substantially the same results are obtained.
- Example 1 The procedure of Example 1 is repeated, substituting for the methanol, the following lower alkanols: ethanol, i-propanol, t-butanol and n-hexanol. Substantially the same results are obtained.
- Example 1 The procedure of Example 1 is repeated, substituting for the ethylene glycol dimethyl ether, the following polar inert solvents: dioxane, dimethylformamide and dimethylacetamide. Substantially the same results are obtained.
- Example 1 The procedureof Example 1 is repeated, substituting for acetic anhydride, stoichiometrically equivalent amounts of acetyl chloride and acetyl bromide. Substantially the same results areobtained.
- Example 1 The procedure of Example 1 is repeated, substituting for the acetic anhydride, stoichiometrically equivalent amounts of n-propionic anhydride, i-propionic anhydride, n-butyric anhydride, n-pentanoic anhydride and n-hexanoic' anhydride.
- Example 8 The procedure of Example l is repeated, substituting for til-13 methylgona-1,3,5(10),8-tetraene-3,17,8-diol, stoichiand the following 3-(lower)acyloxy-13-alkylgona (and 8- isogona)-l,3,5(10)-triene-17fi-ols and analogs are obtained:
- dl-l3-methylgona-1,3,5(l0),8- tet1'aene-3,16a,17[3-triol, 3-acetate is prepared from dl-l3- methylgona 1,3,5 (l0),8 tetraene-3,16a,l7;8-triol; dl-13- methyl 1,3,5 (10),7-tetraene-3,16oc,17/3-triol, 3-acetate is prepared from dl-13-methylgona1,3,5 1.0) ,7-tetraene-3, 16a,175-triol; and dl-l3-ethylgona-1,3,5(10),8,14-pentaene- 3,16u,17B-triol, 3-acetate is prepared from dl-13-ethylgona-1,3,5(10),8,14-pentaene-3,16a,17,B-tri0l.
- R and Y are as hereinabove defined by:
- Step (c) reacting the mixture of Step (b) with at least about one equivalent of a (lower) acyl anhydride or (lower) acyl halide until conversion of the anionic form of the 3-hydroxyl group to a (lower)acyloxy group is substantially complete;
- Step (d) recovering the product of Step 2.
- said alkali metal alkoxide is sodium methoxide and said lower alkanol medium is methanol.
- Step (b) said polar inert solvent medium is ethylene glycol dimethyl ether.
- Step (c) is carried out at a temperature of from about 25 C. to about 100 C. for from about minutes to about three hours.
- Step (c) reacting the mixture of Step (b) with acetic anhydride
- d-IS-methylgona-1,3,5(10)-triene-3,17fi-diol, 3-acetate is prepared by (a) reacting d-13-methylgona-1,3,5(10)-triene- 3,175-
- Step (c) reacting the mixture of Step (b) with acetic anhydride
- a process as defined in claim 1 wherein 13-ethylgona-1,3,5(10),8,14-pentaene-3,17 3-diol, 3-acetate is prepared by (a) reacting 13 ethylgona 1,3,5(10),8,14-pentaene-3,
- Step (c) reacting the mixture of Step (b) with acetic anhydride
- a process as defined in claim 1 wherein l3-ethylgona-1,3,5(10)-triene-3,16a,17;8-trio1, 3-acetate is prepared by (a) reacting 13-ethylgona-1,3,5(10)-triene 3,16a,17,8-
- triol with sodium methoxide in methanol
- Step (b) removing the methanol by vacuum distillation and adding ethylene glycol dimethyl ether; v (c) reacting the mixture of Step (b) with acetic anhydride;
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Description
United States Patent PROCESS FOR SELECTIVELY ACYLATING THE 3- 0L GROUP IN POLYHYDROXY 13-ALKYL GONA- (AND 8 ISOGONA) 1,3,5 TRIENES AND DELTA 7 DELTA 8(9), DELTA 9(11) AND DELTA 8(9),14(15) DEHYDRO DERIVATIVES THEREOF Reinhardt P. Stein, Conshohockeu, and Herchel Smith, Wayne, Pa., assignors to American Home Products Corporation, New York, N.Y., a corporation of Delaware No Drawing. Filed Dec. 26, 1967, Ser. No. 693,112 Int. Cl. C07c 167/28, 169/08; A61k 27/00 U.S. C]. 260-3975 11 Claims ABSTRACT OF THE DISCLOSURE Polyhydroxy 13-alkylgona-(and 8-isogona)-1,3,5(l0)- triene 3-ols and A A A and A dehydro' analogs thereof are selectively acylated in the 3-position by reaction with alkali metal alkoxide in a lower alkanol, displacement of the lower alkanol with a polar inert solvent and acylation in said solvent. The products of the process are hormonally active, especially estrogenically' and anti-lipemically active and also are useful as intermediates in the preparation of hormonally active steroids, such as 17u-ethynylestradiol.
This invention is concerned with the preparation of steroid compounds useful in therapy and as intermediates for therapeutically useful compounds. More particularly, it relates to a new and useful process for the selective acylation of the phenolic hydroXyl function of A-ring aromatic, polyhydroxylated steroids. Compounds prepared by this process are estrogenically and anti-lipemicallyactive and are important intermediates in the preparation of biologically active steroids.
BACKGROUND OF THE INVENTION Those skilled in the art of steroid chemistry often re quire means to protect a reaction-labile group. before transformation of another remote functional group, and then a means to regenerate the protected group. For example, in the preparation of biologically-active 3-hydroxy steroids with transformed C-l7 functions from readily available 3,17-dihydroxy starting materials, it would be of substantial benefit to be able selectively to protect the 3-hydroxy group in such a way that the protective group can later be removed. Such a means would permit, for example, the preparation of 17a-ethynylestradiol, a,conipound widely used in anovulatory compositions, from estradiol (instead of from estrone, ,as now is done) by formation of a ,3-acyloxyestradiol, oxidation of the 17 hydroxymethylene group to 17-keto,,transformation of 17-keto to l7a-ethynyl-l7fi-hydroxy, and removal of the protective 3-acylate so as to regenerate a 3-phenolic hydroxl group. However, those skilled in the art would view such a proposal with some pessimism since any acylating agent capable of reacting with the 3-ol group is just as likely to react with other hydroxyl groups, especially with 1718-01 groups. It has now surprisingly been found that with careful selection of reaction conditions and by making a judicious choice of solvents sucha selective 3-acylation of polyhydroxy steroids can readily be accomplished.
It is, accordingly, a primary object of this invention to provide a means selectively to acylate the 3-01 group in polyhydroxylated, A-ring aromatic steroids.
It is a further object to provide a selective means to protect the 3-hydroxyl group in a polyhydroxylated, A- ring aromatic steroid,to transform other functional groups in the steroid, and then to regenerate the S-hydroxyl group.
It is another object of the instant invention to provide an improved means to obtain selectively 3-acylated, polyhydroxylated, A-ring aromatic steroids useful for their estrongenic and anti-lipemic properties.
DESCRIPTION OF THE INVENTION These and other objects of this invention are readily obtained by practice of the instant invention which is, in essence: a process for the preparation of a 3-(lower) acyloxy-13-alkylgonav(and S-isogona) 1,3,5 (IO-trien- 175-01 of Formula I OH I acylating the 3-hydroxy group of a corresponding polyhydroxylated steroid compound of Formula II:
wherein R and Y are as hereinabove defined by:
(a) reacting said'polyhydroxylated steroid with at'least about one equivalent of an alkali metal (lower)alkoxide in a lower alkanol medium until conversion of the 3-hydroxyl group'to the corresponding anionic form is substantially complete;
' (b) displacing said lower alkanol inert solvent medium,
(c) reacting the mixture of Step (in) with at least about one equivalent of "a (lower-)acyl anhydride or (lower)v acyl halide until conversion of the anionic form of the 3-hydroxyl group to a (lower)acy1oxy group is substan' tially complete; and v (d) recovering the product of Step (0)).
Special mention is made of'a number of important embodiments of the instant invention.
These are respectively: 1
A process as next'above defined wherein,in Step (a), said alkali metal alkoxide is sodium methoxide and said lower alkanol medium is methanol;
A process as first above defined wherein, in Step" (b) said polar inert solvent medium is ethylene glycol dimethyl ether. v
A process as first above defined wherein Step (c) is carried out at a temperatureof from about 25 C. to about C. for from about 15 minutes to about three ours.
medium with a polar A process as first above defined wherein l3-methylgona- 1,3,5 (10)8-tetraene-3,17fi-diol, 3-acetate is prepared by (a) reacting 13-methylgona-1,3,5(10),8-tetraene-3,17- diol with sodium methoxide in methanol;
(b) removing the methanol by vacuum distillation and adding ethylene glycol dimethyl ether;
(c) reacting the mixture of Step (b) with acetic anhydride; and
(d) recovering the product by removing the solvent by distillation in a vacuum.
A process as first above defined wherein 13-ethylgona- 1,3,5 10),8-tetraene-3,17{3-diol, 3 acetate is prepared by (a) reacting 13 ethylgona-1,3,5(l),8-tetraene-3,17{3- diol with sodium methoxide in methanol;
(b) removing the methanol by vacuum distillation and adding ethylene glycol dimethyl ether;
(c) reacting the mixture of Step (b) with acetic anhydride; and
(d) recovering the product by removing the solvent by distillation in a vacuum.
A process as first above defined wherein d-13-methylgona-1,3,5(l0)-triene-3,l7fi-diol, 3-acetate is prepared by (a) reacting d l3-methylgona-1,3,5(l0)-triene-3,17fldiol with sodium methoxide in methanol;
(b) removing the methanol by vacuum distillation and adding ethylene glycol dimethyl ether;
(c) reacting the mixture of Step (b) with acetic anhydride; and
(d) recovering the product by removing the solvent by distillation in a vacuum.
A process as first above defined wherein l3-methylgona- 1,3,5(),7-tetraene-3,17 3-diol, 3-acetate is prepared by (a) reacting 13-methylgona-l,3,5(10),7-tetraene-3,l7fldiol with sodium methoxide in methanol;
(b) removing the methanol by vacuum distillation and adding ethylene glycol dimethyl ether;
(c) reacting the mixture of Step (b) with acetic anhydride; and
(d) recovering the product by removing the solvent by distillation in a vacuum.
A process as first above defined wherein 13-ethylgona- 1,3,5 (10),9(l1)-tetraene-3,17,8-diol, 3-acetate is prepared y (a) reacting l3 ethylgona-1,3,5(10),9(l1)-tetraene-3, l7fl-diol with sodium methoxide in methanol;
(b) removing the methanol by vacuum distillation and adding ethylene glycol dimethyl ether;
(c) reacting the mixture of Step (b) with acetic anhydride; and
/ (d) recovering the product by removing the solvent by distillation in a vacuum.
A process as first above defined wherein 13-ethylgona- 1,3,5 (l0),8,14-pentaene-3,17/3-diol, 3-acetate is prepared (a) reacting 13 ethylgona-1,3,5(10),8,l4-pentaene-3, 17/3-diol with sodium methoxide in methanol;
(b) removing the methanol by vacuum distillation and adding ethylene glycol dimethyl ether; 1
(c). reacting the mixture of Step (b) with acetic anhydride; and 1 (d) recovering the product by removing the solvent by distillation in a vacuum.
A process as first above defined wherein l3-ethylgona- 1,3,5 (10)-triene-3,16a,17fl-triol, 3-acetate is prepared by (a) reacting 13 ethylgona-1,3,5(10)-triene-3,16a,17,8- triol with sodium methoxide in methanol; I
(b). removing the methanol by vacuum distillation and adding ethylene glycol dimethyl ether;
(c) reacting the mixture of Step (b) with acetic anhydride;;and H (d) recovering the product by removing the solvent by distillationin a vacuum.
In the specificationand in the appended claims the term (lower)alkyl contemplates saturated hydrocarbon radito about 6 carbon atoms and includes, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, n-hexyl, 3-methyl pentyl, and the like. The term (lower)acyl contemplates alkanoyl groups, both straight chain or branched, or from about 1 to about 6 carbon atoms and includes, for example, formyl acetyl, n-propionyl, n-butyroyl, i-butyroyl, n-pentanoyl, n-hexanoyl, 3- methylpentanoyl, and the like. The term (lower) alkanol contemplates aliphatic alcohols, straight and branched chain, containing from about 1 to about 6 carbon atoms and includes, for example, methanol, ethanol, n-propanol, i-propanol, n-butanol, t-butanol, n-pentanol, n-hexanol, 3-methylpentanol, and the like. The term alkali metal (lower)alkoxide contemplates organometallic derivatives of lithium, potassium, sodium, cesium and rubidium and (lower) alkanols and includes, for example, sodium methoxide, potassium methoxide, lithium methoxide, cesium methoxide, rubidium methoxide, sodium ethoxide, sodium n-propoxide, sodium i-propoxide, sodium n-butoxide, sodium t-butoxide, potassium t-butoxide, sodium n-pentoxide, sodium n-hexoxide and the like. The term (lower)acyl anhydride contemplates compounds containing (lower)alkanoyl groups as above defined and includes, for example, acetic anhydride, n-propionic anhydride, n-butyric anhydride, i-butyric anhydride, n-pentanoic anhydride, n-hexanoic anhydride and the like. The term (lower)acyl halide contemplates lower(acyl) halogenides derived from fluorine, chlorine, bromine and iodine, the (lower)acyl group being as above illustrated, and includes, for example, acetyl fluoride, acetyl chloride, acetyl bromide, acetyl iodide, n-propionyl chloride, n-butyroyl chloride, i-butyroyl chloride, n-pentanoyl chloride, n-hexanoyl chloride, 3-methylpentanoyl chloride, and the like. The term polar inert solvent medium contemplates solvents, organic and inorganics, which are polar in nature and are not susceptible to reaction with (lower)acyl anhydrides or (lower)acyl halides under the conditions exemplified and includes, for example, ethylene glycol dimethyl ether, dioxane, dimethylformamide, dimethylacetamide, and the like.
Starting materials of Formula II herein are commercially available or can readily be prepared by techniques familiar to those skilled in the art. For example, d-estradiol, a compound of Formula II wherein R is methyl is an item of commerce.
The 13-alkylgona 1,3,5(10) triene 3,17/3 diols of Formula II are prepared by means exemplified by Gordon Alan Hughes and Herchel Smith in copending US. patent application No. 534,353 filed Mar. 15, 196 6.
The 13 alkyl 8 isogona 1,3,5(10) triene 3,17/3- diols of Formula II are prepared by means exemplified by Gordon Alan Hughes and Herchel Smith in copending US. patent application Ser. No. 461,909, filed June 7, 1965, now US. 3,407,217.
The 13 alkylgona 1,3,5(l0),7 tetraene 3,175- diols of Formula II are prepared by means exemplified by R. P. Stein, G. C. Buzby, Jr., and Herchel Smith in copending US. patent application Ser. No. 559,175, filed June 21, 1966, now abondoned.
The 13 alkylgona 1,3,5(l0),8(9)tetraene 3,17/3- diols of Formula II are prepared by means exemplified by Gordon Alan Hughes and Herchel Smith in copending US. patent application Ser. No. 467,419, filed June 28, 1965, now US. 3,391,169.
The 13 alkylgona 1,3,5(10),9(11)tetraene 3,17,3- diols of Formula II are prepared by means exemplified by Gordon Alan Hughes and Herchel Smith in copending US. patent application Ser. No. 488,936, filed Sept. 21, 1965, now US. 3,391,170. 7
The 13 alkylgona 1,3,5(l0),8(9),14(15)pentaene- 3,17 3-diols of Formula II are prepared by means exemplified by Gordon Alan Hughes and Herchel Smith in US. 3,202,686. 1
In carrying out Step (a) of the instant process, the steroid of Formula II may be added to a mixture of the alkali metal (lower)alkoxide and the (lower)alkanol at any convenient temperature, e.g. from about 10 C. to
about 50 C., or even higher. It is preferred to use at leastabout one equivalent amount of the alkali metal (lower)alkoxide, or a slight excess, e.g., up to about a 10% excess, based on the steroid starting material. The reaction forming the anion salt, especially at about 25 C., is quite rapid and 'is substantially complete almost instantaneously.
In carrying out Step (b), displacement of the (lower) alkanol by the polar inert solvent, resort can be made to adding the solvent and fractionally distilling off the (lower) alkanol. However, especially in cases where the respective boiling points are close, it is preferred and convenient first to distill off the (lower)alkanol, then to resuspend the residue in the desired volume of inert polar solvent.
In carrying out Step reaction of the product of Step (b) with the acylating agent, which may be a (lower)acyl anhydride, (lower)acyl halide, or obvious chemical equivalent thereof, such as, for example a (lower)acyl p-toluenesulfonate, the acylating agent can be aded to the mixture at temperatures of from about 10 C. to about 150 C., but preferably at from about 25 C. to about 100 C. It is preferred to use at least about one equivalent amount of the acylating agent, or a slight excess, e.g., up to about a 10% excess, based on the steroid. The reaction forming the desired selectively acylated product is substantially complete, depending on the temperature, in from about 15 minutes to several, e.g., about 3, hours.
After selective acylation is complete, recovery of the product of Formula I according to Step (d) is accomplished by conventional methods. For example, sometimes the product can be induced to precipitate by cooling the mixture, especially if it first has been concen trated, then the precipitate is recovered by filtration. One especially useful means is to distill oif all of the reaction solvent, leaving the product as a residue. To proceed in this manner, the solvent is distilled off in a vacuum. Any excess acylating agent can be decomposed by adding ammonium chloride solution. The mixture then can be extracted with a water immiscible organic solvent, such as ethyl acetate, and the extract can be washed with water, saturated sodium chloride solution and dried over anhydrous sodium sulfate. Evaporation of the solvent leaves the product of Formula I as a residue. If desired, it may be further purified by chromatography: it is dissolved in chloroform and passed through a column of active silica gel. The eluates can be combined and evaporated. The residue can often be induced to crystallize by trituration with ether or isopropanol and can be recrystallized from a (lower)alkanol.
The time and temperature ranges used in describing the aforementioned process steps simply represent the most convenient ranges consistent with carrying out the reaction in a minimum of time without undue difficulty. Thus, reaction temperatures appreciably below these can be used, but their use considerably extends the reaction time. Similarly, reaction temperatures higher than those mentioned can be employed with a concomitant decrease in reaction time, although purity of the product may be somewhat decreased.
The sources for the startingmaterials ofFormula II have been specified hereinabove. Generally, all can be prepared by totally synthetic processes described by Douglas, Graves, Hartley, Hughes, McLoughlin, Siddall and Smith in J. Chem. Soc., 1963 pages 5077-94. In the product of a total synthesis which has not included a suitable resolution stage the compounds prepared by the invention will be present as racemates. Using a convention approved by Fieser and Fieser, Steroids, p. 336 (1959), the compounds designated as the d-forms are the enantiomers corresponding in configuration at C-13 to that of the natural hormone estrone. The corresponding enantiomorphs are consequently designated the l-forms and the racemates the dl-forms. Racemates will be depicted by structural formulas which show only the enantiomorphs of the d-configuration.
As is mentioned hereinabove, the compounds of Formula I prepared by this process have estrogenic and antilipemic activity. This makes them useful to treat conditions in mammals responsive to treatment with estogenic drugs, such as, for example, menopause, senile vaginitis, kraurosis vulvae, pruritis vulvae and the like. In addition they are useful to lower blood lipid level of mammals and can be used whenever anti-lipemic agents are indicated, such as in the treatment of various hyperlipid aemias or where the incidence of atherosclerosis is to be minimized. The products prepared by the instant process are also useful as intermediates for the preparation of other steroids, such as 17a-ethynylestradiol as mentioned above which have hormonal or other useful activities.
The products of Formula I prepared by this invention can be used in association with a pharmaceutically acceptable carrier. They can be formulated in liquid or solid forms, for instance as capsules, tablets, suppositories, powders, dispersible granules, cachets, and the like, by combining them with conventional carriers. Such conventional carriers include magnesium carbonate or stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, low melting wax and cocoa butter. Diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders or tablet-disintegrating agents can be used. Powders or tablets preferably contain 5 or 10 to 99% of the active constituent. The active steroid can be formulated with an encapsulating material with or Without other carriers.
Liquid preparations such as solutions, suspensions or emulsions can also be used. Such preparations include dispersions in a pharmaceutically acceptable carrier such as arachis oil or sterile water, preferably containing a non-ionic surface active agent such as fatty acid esters of polyhydroxy compounds, e.g., sorbitan, aqueous starch in sodium carboxymethylcellulose solutions, aqueous propylene glycol or polyethylene glycol. Thus a waterpropylene glycol solution can be used for parenteral injection and aqueous suspensions suitable for oral use can be made by utilizing natural or synthetic gums, resins, methyl cellulose or other well known suspending agents.
The composition can be in unit dose form in which the dose unit is for instance from about 0.1 to about 200 mg. of each active steroid. The unit dose form can be a packaged composition, e.g., packeted powder, vials or ampules or, for example, in the form of capsules, cachets or tablets or any number of these in packaged form. The pharmaceutical compositions can also consist substantially solely of the active steroid when this is in unit dose form. When used for the purposes stated above, the dosage of the compounds will vary with the condition being treated, but in general Will be in the range established for estradiol (Merck Index, seventh edition, p. 416 (1960)).
d-Estradiol-3-acetate, one of the products prepared by the instantprocess (and which itself is the subject of US. 2,156,599), can be used at a level of 1.25 mg. daily, orally, in menopausal syndrome and from 1.25 to 3.75 mg. or more, daily, for senile vaginitis, kraurosis vulvae or pruritis vulvae, in warm blooded animals of about 70 kilogram average body weight, depending on the tissue response of the individual.
Of course, as will be clear to those skilled in the art, in addition to compound designated by Formula -II, the process broadly can be applied to obvious chemical equivalents thereof but differing therefrom in the sense of having other functional groups attached to the steroid nucleus, whenever such groupsdo not themselves inter-.
fere or become affected by the process, unless, in exceptional instances, this is a desired effect. Broadly stated, therefore, useful substrates would be represented by the formula wherein n is at least two and R is a cyclopentanopolyhydrophenanthrene nucleus monohydroxylated in its aromatic A-ring which, on selective acylation at the 3-position, would provide a product with anti-lipemic and estrogenic activity.
DESCRIPTION OF THE PREFERRED EMBODIMENTS The following examples are given by way of illustration and are not to be construed as limitations of this invention, variations of which are possible without departing from the scope and spirit thereof.
Example 1 dl-l3-methylgona-l, 3,5(10),8 tetraene-3,17,8 diol, 3- acetate.Add dl-l3-methylgona-1,3,5(l0), 8-tetraene-3, 17/3-diol, 2.70 g., to a solution of sodium methoxide (0.594 g.) in anhydrous methanol (40 ml.). Stir, then remove the solvent in vacuo. Add ethylene glycol dimethyl ether (100 ml.) to the residue and stir, then add a solution of acetic anhydride (1.12 g.) in ethylene glycol dimethyl ether (15 ml.). Stir the reaction for 15 min. at room temperature, heat on a steam bath for 15 min. then stir again at room temperature for 15 min. Remove the solvent in vacuo. Decompose the residue with ammonium chloride solution (200 ml.). Extract the mixture with ethyl acetate and wash the extract with water and saturated sodium chloride solution then dry over anhydrous sodium sulfate. Filter and remove the solvent in vacuo. Dissolve the residue in chloroform and pass the solution through a column of active silica gel. Wash the column well with chloroform then combine the eluates and remove the solvent in vacuo. Add a small amount of ether to the residue to initiate crystallization. Cover the resulting solid with isopropanol and filter the crude title product to get 1.45 g. of near-white prisms, M.P. 143- 145. Further purify a sample by treating a methylene chloride solution with decolorizing charcoal, filtering through filter aid and replacing the methylene chloride with isopropanol by boiling on the steam bath. Allow the solution to stand to fully crystallize. Filter the resulting white prisms to get the pure title product; M.P. 146-148;
mg; 3.02 and 5.68 x532? 277 66,. (El-1,800)
Calcd. for C H O C, 76.89; H, 7.74. Found: C, 76.93; H, 7.74.
Example 2 dl 13 ethylgona-1,3,5(),8-tetraene-3,17[3-diol, 3- acetate.Add dl 13 ethylgona-1,3,5(10),8-tetraene-3, 17fi-diol, 2.84 g., to a solution of sodium methoxide (0.550 g.) in anhydrous methanol (30 ml.). Stir the solution, then remove the solvent in vacuo. Add ethylene glycol dimethyl ether 100 ml.) to the residue and stir, then add acetic anhydride (1.12 g.). Stir the reaction at room temperature for min., heat on a steam bath for 15 min. and stir again at room temperature for 15 min. Remove the solvent in vacuo. Decompose the residue with 5% ammonium chloride solution (100 ml.) then extract well with ethyl acetate. Wash the extract with water and saturated sodium chloride solution then dry over anhydrous sodium sulfate. Filter and remove the solvent in vacuo. Dissolve the resulting solid in chloroform and pass the solution through an active silica gel column.' Elute with chloroform and evaporate the solvent in vacuo. Purify the solid residue by dissolving in methylene chloride, treating with decolorizing charcoal and filtering through super cel. Re-
place the methylene chloride with isopropanol by boiling 2.87, 2.97 (hydroxyl doublet) max.
m 277 mu (6 14,200
Calcd. for C H O C, 77.27; H, 8.03. Found: C, 77.03; H, 7.72.
Example 3 d-13-methylgona 1,3,5(10) triene-3,17fi-diol, 3acetate (d-estradiol3-acetate).Dissolve de-estradiol (2.72 g.) in a solution containing sodium methoxide (0.594 g.) in anhydrous methanol. ml.). Stir, then remove the methanol in vacuo. Add ethylene glycol dimethyl ether (100 ml.) to the residue, stir then add acetic anhydride (1.12 g.). Stir the reaction at room temperature for 15 min.,heat on a steam bath for 15 min. then stir again at room temperature for /2 hour. Remove the solvent in vacuo and decompose the residue with 5% ammonium chloride solution (150 ml.). Extract the mixture with ethyl acetate and wash the extract with water and saturated sodium chloride solution then dry over anhydrous sodium sulfate. Filter and evaporate the solvent in vacuo. Dissolve the residue in chloroform and pass the solution through a column of active'silica gel. Evaporate the chloroform in vacuo to an oil. Cover the oil with a small amount of ether to induce crystallization. Triturate the resulting solid with isopropanol to obtain 0.77 g. of the title product; M.P. l39141;
ass and 5.76 045467 0:1, 6hr
Example 4 d-13-rnethylgonal,3,5 10) ,7-tetraene-3,l7fl-diol, 3-acetate; (d-17-dihydroequilin-3-acetate).Dissolve d 17- dihydroequilin (5.40 g.) in a solution containing sodium methoxide (1.188 g.) in anhydrous methanol ml.). Stir then remove the solvent in vacuo. To the residue add ethylene glycol dimethyl ether (200 ml.), stir then add acetic anhydride (2.3 g.) and continue stirring at room temperature for 1 hour. Remove the solvent in vacuo. Decompose the residue with 5% ammonium chloride solution (250 ml.) and extract the mixture well with ethyl acetate. Wash the extract with water and saturated sodium chloride solution then dry over anhydrous sodium sulfate. Filter, remove the solvent in vacuo and dissolve the residue in chloroform. Pass the solution through active silica gel and elute with chloroform. Evaporate the chloroform in vacuo. Triturate the residue with isopropanol to induce crystallization. Filter to obtain the pure title product as a white crystalline solid.
Example 5 dl 13 ethylgona 1,3,5(10),9(11)-tetraene-3,17/3- diol, 3-acetate.-Add dl-13-ethylgona-1,3,5(10),9(11)- tetraene-3,17,6-diol, 2.84 g., to a solution containing sodium methoxide (0.540 g.) in anhydrous methanol (40 ml.), stir then remove the solvent in vacuo. Add ethylene glycol dimethyl ether ml.) to the residue, stir then add acetic anhydride (1.10 g.) and stir at room temperature for 15 min., heat on a steam bath for 15 min., cool, then remove the solvent in vacuo. Decompose the residue with 5% ammonium chloride solution (100 ml.) and extract with ethyl acetate. Wash the extract with water and saturated sodium chloride solution then dry over anhydrous sodium sulfate. Filter and remove the solvent in vacuo. Dissolve the crystalline residue in methylene chloride, treat with decolorizing charcoal and filter through filter aid. Replace the methylene chloride with isopropanol by boiling on the steam bath. Seed and let stand to crystallize. Filter the resulting white crystals of pure title compound.
Example 6 dl-13-ethylgona-1,3,5(10),8,14-pentaene-3,17/3-diol, 3- acetate.-Add dl 13 ethylgona-1,3,5(10),8,14-pentaene- 3,17B-diol (1.41 g.) to a solution of sodium methoxide (0.275 g.) in anhydrous methanol (25 ml), stir then re move the methanol in vacuo. Add ethylene glycol dimethyl ether (100 ml.), stir then add a solution of acetic anhydride (0.510 g.) in ethylene glycol dimethyl ether (15 ml.). Warm the solution for 10 min. on the steam bath, cool and stir at room temperature for 20 min. Remove the solvent in vacuo and decompose the residue, with ammonium chloride solution (100 ml.). Extract the mixture well with ethyl acetate. Wash the extract with water and saturated sodium chloride solution then dry over anhydrous sodium sulfate. Filter and remove the solvent in vacuo. Triturate the residue with isopropanol and filter to obtain the title product. 1
Example 7 r The procedure of Example 1 is repeated, substituting for the sodium methoxide, stoichiometrically equivalent amounts of the following alkali metal (lower )alkoxides: potassium methoxide, lithium methoxide, sodium ethoxide, potassium t-butoxide and sodium n-hexoxide. Substantially the same results are obtained.
The procedure of Example 1 is repeated, substituting for the methanol, the following lower alkanols: ethanol, i-propanol, t-butanol and n-hexanol. Substantially the same results are obtained.
The procedure of Example 1 is repeated, substituting for the ethylene glycol dimethyl ether, the following polar inert solvents: dioxane, dimethylformamide and dimethylacetamide. Substantially the same results are obtained.
The procedureof Example 1 is repeated, substituting for acetic anhydride, stoichiometrically equivalent amounts of acetyl chloride and acetyl bromide. Substantially the same results areobtained.
The procedure of Example 1 is repeated, substituting for the acetic anhydride, stoichiometrically equivalent amounts of n-propionic anhydride, i-propionic anhydride, n-butyric anhydride, n-pentanoic anhydride and n-hexanoic' anhydride. There are obtained, respectively, dl-l3-methylgona-1,3,5(10),8-tetraene-3,17B-diol, 3Tn-propionate; dl- 13-methylgona-1,3,5(10),8-tetraene-3,17B-diol, 3-i-propionate; dl-13-methylgona-1,3,5(10),8-tetraene-3,17fl-diol 3- n butyrate; dl-13-methylgona-1,3,5 (10),8-tetraene-3,17fldiol, n pentanoate, and'dl-13-methylgona-1,3,5(l0),8- tetraene-3,17fl-diol, n-hexanoate.
Example 8 The procedure of Example l is repeated, substituting for til-13 methylgona-1,3,5(10),8-tetraene-3,17,8-diol, stoichiand the following 3-(lower)acyloxy-13-alkylgona (and 8- isogona)-l,3,5(10)-triene-17fi-ols and analogs are obtained:
dl-13-ethylgona-1,3,5(10)-triene-3,16a,1.7B-triol, 3-acetate.--Add dl 13 ethylgona-1,3,5( l0)-triene-3,16a,17fitriol (prepared by the procedure of Example 177 in Ser. No. 534,353, filed Mar. 15, 1966, 1.41 g.) to a solution of sodium methoxide (0.275 g.) in anhydrous methanol (25 ml.), stir then remove the methanol in vacuo. Add ethylene glycol dimethyl ether ml.), stir then add a solution of acetic anhydride (0.510 g.) in ethylene glycol dimethyl ether (15 ml.). Warm the solution for 10 min. on the steam bath, cool and stir at 22 C. for 20 min. Remove the solvent in vacuo and decompose the residue with 5% ammonium chloride solution (100 ml.). Extract the mixture well with ethyl acetate. Wash the extract with water and saturated sodium chloride solution then dry over anhydrous sodium sulfate. Filter and remove the solvent invvacuo. Triturate the residue with isopropanol and filter to obtain the title product.
In a similar manner, dl-l3-methylgona-1,3,5(l0),8- tet1'aene-3,16a,17[3-triol, 3-acetate is prepared from dl-l3- methylgona 1,3,5 (l0),8 tetraene-3,16a,l7;8-triol; dl-13- methyl 1,3,5 (10),7-tetraene-3,16oc,17/3-triol, 3-acetate is prepared from dl-13-methylgona1,3,5 1.0) ,7-tetraene-3, 16a,175-triol; and dl-l3-ethylgona-1,3,5(10),8,14-pentaene- 3,16u,17B-triol, 3-acetate is prepared from dl-13-ethylgona-1,3,5(10),8,14-pentaene-3,16a,17,B-tri0l.
What is claimed is: p v
1. A process for the preparation of a 3-(lower)acyloxy- 13-alkylgona-(and 8-isogona) 1,3,5 (l0)-trien-17fl-ol of the formula p I and the A''-, the A and A and the A8(9)-14(15)- dehydro analogs thereof, wherein R and R are lower alkyl; Y is methylene or hydroxymethylene, the symbol (5) indicates ocor ficonfiguration, and the broken lines indicate unsaturation in said analogs, which comprises selectively acylating the 3-hydroxy group of a corresponding polyhydroxylated steroid compound of the formula:
1 1 wherein R and Y are as hereinabove defined by:
(a) reacting said polyhydroxylated steroid with at least about one equivalent of an alkali metal (lower)alk oxide in a lower alkanol medium until conversion of the 3-hydroxyl group to the corresponding anionic form is substantially complete;
(b) displacing said lower alkanol medium with a polar inert solvent medium;
(c) reacting the mixture of Step (b) with at least about one equivalent of a (lower) acyl anhydride or (lower) acyl halide until conversion of the anionic form of the 3-hydroxyl group to a (lower)acyloxy group is substantially complete; and
(d) recovering the product of Step 2. A process as defined in claim 1 wherein, in Step (a), said alkali metal alkoxide is sodium methoxide and said lower alkanol medium is methanol.
3. A process as defined in claim 1 wherein, in Step (b) said polar inert solvent medium is ethylene glycol dimethyl ether.
4. A process as defined in claim 1 wherein Step (c) is carried out at a temperature of from about 25 C. to about 100 C. for from about minutes to about three hours.
5. A process as defined in claim 1 wherein 13-methylgona-1,3,5 (10),8-tetraene-3,17fl-diol, 3-acetate is prepared y (a) reacting 13-methylgona-l,3,5(10),8-tetraene-3,17,B-
diol with sodium methoxide in methanol;
(b) removing the methanol by vacuum distillation and adding ethylene glycol dimethyl ether;
(c) reacting the mixture of Step (b) with acetic anhydride; and
(d) recovering the product by removing the solvent by distillation in a vacuum.
6. A process as defined in claim 1 wherein 13-ethylgona-1,3,5(10),8-tetraene-3,17fi-diol, 3-acetate is prepared y (a) reacting l3-ethylgona-1,3,5(10),8-tetraene 3,175-
diol with sodium methoxide in methanol;
(b) removing the methanol by vacuum distillation and adding ethylene glycol dimethyl ether;
(0) reacting the mixture of Step (b) with acetic anhydride; and
(d) recovering the product by removing the solvent by distillation in a vacuum.
7. A process as defined in claim 1 wherein d-IS-methylgona-1,3,5(10)-triene-3,17fi-diol, 3-acetate is prepared by (a) reacting d-13-methylgona-1,3,5(10)-triene- 3,175-
diol with sodium methoxide in methanol;
(b) removing the methanol by vacuum distillation and adding ethylene glycol dimethyl ether;
(0) reacting the mixture of Step (b) with acetic anhydride; and
(d) recovering the product by removing the solvent by distillation in a vacuum.
8. A process as defined in claim 1 wherein 13-methylgona-1,3,5(10),7-tetraene-3,17/3-diol, 3-acetate is prepared y (a) reacting 13-methylgona-1,3,5(10),7-tetraene-3,17/3- diol with sodium methoxide in methanol;
(b) removing the methanol by vacuum distillation and adding ethylene glycol dimethyl ether;
(c) reacting the mixture of Step (b) with acetic anhydride; and
(d) recovering the product by removing the solvent by distillation in a vacuum.
9. A process an defined in claim 1 wherein 13-ethylgona-1,3,5(10),9(11)-tetraene-3,17p-diol, 3-acetate is prepared by (a) reacting 13-ethylgona-1,3,5(10),9(11)-tetraene-3,
17,8-diol with sodium methoxide in methanol;
(b) removing the methanol by vacuum distillation and adding ethylene glycol dimethyl ether;
(0) reacting the mixture of Step (b) with acetic anhydride; and
(d) recovering the product by removing the solvent by distillation in a vacuum.
10. A process as defined in claim 1 wherein 13-ethylgona-1,3,5(10),8,14-pentaene-3,17 3-diol, 3-acetate is prepared by (a) reacting 13 ethylgona 1,3,5(10),8,14-pentaene-3,
1713-diol with sodium methoxide in methanol;
(b) removing the methanol by vacuum distillation and adding ethylene glycol dimethyl ether;
(c) reacting the mixture of Step (b) with acetic anhydride; and
(d) recovering the product by removing the solvent by distillation in a vacuum.
11. A process as defined in claim 1 wherein l3-ethylgona-1,3,5(10)-triene-3,16a,17;8-trio1, 3-acetate is prepared by (a) reacting 13-ethylgona-1,3,5(10)-triene 3,16a,17,8-
triol with sodium methoxide in methanol;
(b) removing the methanol by vacuum distillation and adding ethylene glycol dimethyl ether; v (c) reacting the mixture of Step (b) with acetic anhydride; and
(d) recovering the product by removing the solvent by distillation in a vacuum.
No references cited.
HENRY A. FRENCH, Primary Examiner US. Cl. X.R.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69311267A | 1967-12-26 | 1967-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3478070A true US3478070A (en) | 1969-11-11 |
Family
ID=24783357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US693112A Expired - Lifetime US3478070A (en) | 1967-12-26 | 1967-12-26 | Process for selectively acylating the 3-ol group in polyhydroxy 13-alkyl gona-(and 8 - isogona) - 1,3,5 - (10) - trienes and delta - 7 -,delta - 8(9),delta - 9(11) -,and delta - 8(9),14(15) - dehydro derivatives thereof |
Country Status (1)
Country | Link |
---|---|
US (1) | US3478070A (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040209856A1 (en) * | 2001-12-21 | 2004-10-21 | Galen (Chemicals) Limited | Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
US8633178B2 (en) | 2011-11-23 | 2014-01-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8933059B2 (en) | 2012-06-18 | 2015-01-13 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US9289382B2 (en) | 2012-06-18 | 2016-03-22 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10052386B2 (en) | 2012-06-18 | 2018-08-21 | Therapeuticsmd, Inc. | Progesterone formulations |
US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10258630B2 (en) | 2014-10-22 | 2019-04-16 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10471148B2 (en) | 2012-06-18 | 2019-11-12 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
-
1967
- 1967-12-26 US US693112A patent/US3478070A/en not_active Expired - Lifetime
Non-Patent Citations (1)
Title |
---|
None * |
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040209856A1 (en) * | 2001-12-21 | 2004-10-21 | Galen (Chemicals) Limited | Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
US20050234028A1 (en) * | 2001-12-21 | 2005-10-20 | Warner Chilcott Company Inc. | Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
US6962908B2 (en) * | 2001-12-21 | 2005-11-08 | Warner Chilcott Company Inc. | Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
US7572779B2 (en) | 2001-12-21 | 2009-08-11 | Warner Chilcott Company Llc | Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
US7799771B2 (en) | 2001-12-21 | 2010-09-21 | Warner Chilcott Company, Llc. | Oral pharmaceutical products containing 17β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
US9248136B2 (en) | 2011-11-23 | 2016-02-02 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US8846648B2 (en) | 2011-11-23 | 2014-09-30 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8846649B2 (en) | 2011-11-23 | 2014-09-30 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8633178B2 (en) | 2011-11-23 | 2014-01-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10675288B2 (en) | 2011-11-23 | 2020-06-09 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8987237B2 (en) | 2011-11-23 | 2015-03-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11103516B2 (en) | 2011-11-23 | 2021-08-31 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11793819B2 (en) | 2011-11-23 | 2023-10-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11166963B2 (en) | 2012-06-18 | 2021-11-09 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9289382B2 (en) | 2012-06-18 | 2016-03-22 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11865179B2 (en) | 2012-06-18 | 2024-01-09 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
US9012434B2 (en) | 2012-06-18 | 2015-04-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10052386B2 (en) | 2012-06-18 | 2018-08-21 | Therapeuticsmd, Inc. | Progesterone formulations |
US11529360B2 (en) | 2012-06-18 | 2022-12-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10639375B2 (en) | 2012-06-18 | 2020-05-05 | Therapeuticsmd, Inc. | Progesterone formulations |
US11110099B2 (en) | 2012-06-18 | 2021-09-07 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9006222B2 (en) | 2012-06-18 | 2015-04-14 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11033626B2 (en) | 2012-06-18 | 2021-06-15 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10471148B2 (en) | 2012-06-18 | 2019-11-12 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8987238B2 (en) | 2012-06-18 | 2015-03-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8933059B2 (en) | 2012-06-18 | 2015-01-13 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11622933B2 (en) | 2012-12-21 | 2023-04-11 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10835487B2 (en) | 2012-12-21 | 2020-11-17 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10888516B2 (en) | 2012-12-21 | 2021-01-12 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11497709B2 (en) | 2012-12-21 | 2022-11-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11351182B2 (en) | 2012-12-21 | 2022-06-07 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11065197B2 (en) | 2012-12-21 | 2021-07-20 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11304959B2 (en) | 2012-12-21 | 2022-04-19 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11116717B2 (en) | 2012-12-21 | 2021-09-14 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11123283B2 (en) | 2012-12-21 | 2021-09-21 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11241445B2 (en) | 2012-12-21 | 2022-02-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11103513B2 (en) | 2014-05-22 | 2021-08-31 | TherapeuticsMD | Natural combination hormone replacement formulations and therapies |
US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10258630B2 (en) | 2014-10-22 | 2019-04-16 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10398708B2 (en) | 2014-10-22 | 2019-09-03 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10668082B2 (en) | 2014-10-22 | 2020-06-02 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10912783B2 (en) | 2015-07-23 | 2021-02-09 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US10532059B2 (en) | 2016-04-01 | 2020-01-14 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3478070A (en) | Process for selectively acylating the 3-ol group in polyhydroxy 13-alkyl gona-(and 8 - isogona) - 1,3,5 - (10) - trienes and delta - 7 -,delta - 8(9),delta - 9(11) -,and delta - 8(9),14(15) - dehydro derivatives thereof | |
US3299107A (en) | 17-(unsaturated hydrocarbon-substituted)-3-hydroxyimino-5alpha-androstan-17beta-ols,alkyl and acyl derivatives thereof | |
US3275666A (en) | 16-methylene steroids of the esterne series | |
US3381003A (en) | 3-keto-13beta-alkyl-17beta-acetyl-gona-4-ene-17alpha-ol compounds and processes of preparing them | |
JPH0276896A (en) | Steroid compound and production thereof | |
US3436411A (en) | Process for cleaving an a-ring ether group in 13-alkylgona (and 8-isogona)-1,3,5(10)-trienes and delta-7-,delta-8(9)-,and delta-8(9),14(15)-dehydro derivatives thereof | |
US2963498A (en) | Dehydro derivatives of 11-oxygenated 17alpha-(lower alkanoyl)-oxy-9alpha-halopregnane-3, 20-diones | |
US3072686A (en) | 16alpha-alkyl-pregnane compounds and process for their manufacture | |
US2855411A (en) | 16-halogen estrone ethers and esters | |
US3646076A (en) | Process for ethynylating 17-keto steroidal phenols | |
US3080399A (en) | Cyclopentanophenanthrene compounds and process | |
US3689512A (en) | Novel 3-etherified-1,3,5(10)-triene-steroids and process thereof | |
JPH026360B2 (en) | ||
US3409643A (en) | Process for the preparation of 17alpha-alkynl-17beta-alkanoyloxy steroids of the androstane and estrane series | |
US2666069A (en) | Method of preparing delta-pregnenes | |
US3423404A (en) | (optionally 17-alkylated) estra-4,9(10)-diene - 3alpha/3beta,17beta - diols and esters corresponding | |
US3143557A (en) | Substituted 19-norandrosta-5(10), 9(11)-dienes and method of preparing same | |
US3467682A (en) | 13beta-alkyl-17alpha-alkynylgon-4-ene-3beta,17beta-diols and esters corresponding | |
US3176030A (en) | 16alpha-lowerhydrocarbon-androsten-16beta-ol-3-one and 16-alpha-lowerhydrocarbon-androsten-16beta-ol-3-ol compounds | |
US3301850A (en) | 17-oxygenated-5alpha-androstane-2alpha, 3alpha-episulfides | |
US2877158A (en) | delta8(14)-9alpha-substituted androstene derivatives | |
US3084173A (en) | Ethinyl and vinyl derivatives of 19-norandrostan-3beta, 17beta-diol | |
IL22646A (en) | 21-esters of pregnane derivatives and a process for their preparation | |
US3029261A (en) | Steroidal fluoro compounds and process for the production thereof | |
US2891076A (en) | 11alpha, 12beta-dimethyl-delta4, 8(14), 13(17)-pregnatriene-3, 20-dione |